Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.